{"disease":{"id":"papillomavirus-infections","name":"papillomavirus infections"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06700941","title":"Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment","phase":"","overall_status":"COMPLETED","enrollment_count":8000000,"lead_sponsor_name":"Universidad Nacional de Colombia","has_results":false},{"nct_id":"NCT01077856","title":"GARDASIL™ Vaccine Impact in Population Study (V501-033)","phase":"","overall_status":"COMPLETED","enrollment_count":54516,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07200414","title":"Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP)","phase":"NA","overall_status":"COMPLETED","enrollment_count":12654,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT05285826","title":"Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8100,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04694495","title":"HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study","phase":"","overall_status":"COMPLETED","enrollment_count":7500,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT04199689","title":"Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6033,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03998254","title":"Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03675256","title":"The KEN SHE Study on HPV-vaccine Efficacy","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":2275,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT04000503","title":"Integrated Cervical Cancer Screening in Mayuge District Uganda (ASPIRE Mayuge)","phase":"NA","overall_status":"COMPLETED","enrollment_count":2019,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT06859151","title":"DNA Methylation and the Increased Risk of Cervical Cancer Development","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT03903562","title":"Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1990,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT00092547","title":"A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1781,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05450705","title":"V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT01073293","title":"A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1054,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04708041","title":"Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":700,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT00496626","title":"An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06399341","title":"Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).","phase":"","overall_status":"COMPLETED","enrollment_count":524,"lead_sponsor_name":"Elpen Pharmaceutical Co. Inc.","has_results":false},{"nct_id":"NCT04772534","title":"Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01245764","title":"GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02858310","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04072913","title":"Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix","phase":"NA","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT03546842","title":"Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05119855","title":"Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03548740","title":"Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection","phase":"","overall_status":"UNKNOWN","enrollment_count":151,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06439433","title":"ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03584308","title":"Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Catalysis SL","has_results":false},{"nct_id":"NCT00380367","title":"Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03981822","title":"A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Verrica Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04115787","title":"Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN","phase":"","overall_status":"UNKNOWN","enrollment_count":104,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT01254643","title":"A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07303751","title":"Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Institut d'Investigació Biomèdica de Bellvitge","has_results":false},{"nct_id":"NCT02631863","title":"Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02845739","title":"PApillomavirus in REnal Transplant Patient","phase":"NA","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT03487549","title":"Cantharidin and Occlusion in Verruca Epithelium","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Verrica Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT06919627","title":"Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04724980","title":"Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":38,"lead_sponsor_name":"Precigen, Inc","has_results":false},{"nct_id":"NCT05797246","title":"Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03929172","title":"A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"2A Pharma AB","has_results":false},{"nct_id":"NCT06854354","title":"Intervention for Human Papillomavirus Vaccine Acceptance in Mexican Mothers","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Hospital Univeristario Benemerita Universidad Autonoma de Puebla","has_results":false},{"nct_id":"NCT03610581","title":"Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT04015336","title":"E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04044950","title":"A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":42},"guidelines":[],"source":"Drug Landscape verified database"}